Heat shock proteins 90-alpha (HSP90
Diagnostic Heat shock proteins 90-alpha (HSP90
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-h-HSP90-Ag01 | Recombinant human HSP90AA1/HSP90 | 3090 |
GMP-h-HSP90-Ab01 | Anti-human HSP90AA1/HSP90 | 1953 |
GMP-h-HSP90-Ab02 | Anti-human HSP90AA1/HSP90 | 1953 |
GMP-h-HSP90-Ab03 | Anti-human HSP90AA1/HSP90 | 1953 |
GMP-h-HSP90-Ab04 | Anti-human HSP90AA1/HSP90 | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-h-HSP90-Ag01 |
Product Name | Recombinant human HSP90AA1/HSP90 |
Target/Biomarker | Heat shock proteins 90-alpha (HSP90(HSP90) |
Alias of Target/Biomarker | EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, Hsp103, Hsp89, Hsp90, LAP-2, LAP2 |
Expression platform | mammalian |
Isotypes | Recombinant Antigen |
Bioactivity validation | Heat shock proteins 90-alpha (HSP90 (HSP90) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HSP90 level test of Cancer (renal cancer, liver cancer and breast cancer) and related syndrome evaluation. |
Products description | Recombinant human HSP90AA1/HSP90 was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-h-HSP90-Ab01, GMP-h-HSP90-Ab02, GMP-h-HSP90-Ab03, GMP-h-HSP90-Ab04 |
Product Name | Anti-human HSP90AA1/HSP90 |
Target/Biomarker | Heat shock proteins 90-alpha (HSP90(HSP90) |
Alias of Target/Biomarker | EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, Hsp103, Hsp89, Hsp90, LAP-2, LAP2 |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Human Heat shock proteins 90-alpha (HSP90 (HSP90) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Heat shock proteins 90-alpha (HSP90 (HSP90) antibodies in HSP90 level test of Cancer (renal cancer, liver cancer and breast cancer) and related syndrome evaluation. |
Tag | mFc |
Products description | Anti-human HSP90AA1/HSP90 is a monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
The Hsp90 family of heat shock proteins represents one of the most abundantly expressed and highly conserved families of cellular chaperones whose expression can be upregulated under conditions of cellular stress, and includes cytoplasmic (Hsp90-alpha/beta), ER (grp94), and mitochondrial (TRAP1) localized members. Structurally, Hsp90 is characterized by an N-terminal ATP-binding domain, a medial substrate-binding domain, and a C-terminal dimerization motif. Hsp90 dimers function in cooperation with cochaperones (e.g. Hsp40, Hsp70, Hop, p23) to stabilize a multitude of client protein substrates, including steroid hormone receptors, protein kinases, and transcription factors. The essential binding and hydrolysis of ATP by Hsp90 is inhibited by ansamycin drugs (e.g. geldanamycin, 17-AAG) which occupy the N-terminal Hsp90 nucleotide-binding pocket. Many Hsp90 client proteins such as erbB2/Her-2, c-raf, bcr-abl, p53, and hTERT, are members of well characterized oncogenic pathways, making Hsp90 inhibitors useful anticancer agents.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.